A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Major Depressive Disorder
Спонсор: Janssen Cilag International
Налично на:
БГ
Обобщение
Trial status: Authorised
Change from baseline (Day 1, predose) at 24 hours post first dose in depressive symptoms, as measured by the CDRS-R total score
Кой може да участва
Age group: 0-17 years
Gender: Female, Male
Target enrollment: 96 participants
БГ
EN